Itolizumab is a Monoclonal Antibody owned by Biocon, and is involved in 20 clinical trials, of which 12 were completed, 6 are ongoing, and 2 are planned.
Itolizumab is a humanized monoclonal antibody that blocks the activity of CD6, a specific antigen found on the surface of an important cell type in the immune system, T cells. CD6 is expressed on the surface of mature human thymocytes, in T lymphocytes of peripheral blood, constituting the majority of the CD3+ cell population, in a subtype of B lymphocytes and in the neurons of the brain cortex. In the T lymphocytes of peripheral blood it participates in the mechanisms of cellular activation. T1h suppresses T cell proliferation and is expected to modify the course of arthritic disease in the clinic by modulating T cell behavior.
The revenue for Itolizumab is expected to reach a total of $1.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Itolizumab NPV Report.
Itolizumab (T1h, Alzumab / Anti-CD6 ) is a humanized recombinant anti-CD6 monoclonal antibody. It is formulated as injection solution for intravenous infusion. It is indicated for the treatment of patients with active moderate to severe chronic plaque psoriasis who are candidates for systemic therapy. Alzumab is indicated for emergency use in the treatment of cytokine release syndrome (CRS) in moderate to severe ARDS (acute respiratory distress syndrome) patients due to COVID-19.
The drug candidate is under development for the treatment of Coronavirus disease 2019 (COVID-19), systemic lupus erythematosus, acute graft-versus-host disease (aGVHD), lupus nephritis, asthma, ulcerative colitis and chronic graft-versus-host disease (cGVHD). It is administered intravenously and subcutaneously. It was also under development for vitiligo, psoriatic arthritis, psoriasis, rheumatoid arthritis, multiple sclerosis, dermatological disorders, refractory lupus nephritis and severe asthma.
Equillium formerly Attenuate Biopharmaceuticals Inc, is a biotechnology company specialized on immunobiology to develop medicines for the treatment of autoimmune and inflammatory disorders. The company’s pipeline product include EQ001 (itolizumab), a first-in-class monoclonal antibody that targets the novel immune checkpoint receptor CD6 that inhibits pathogenic cellular pathways for effector T cell development. Equillium develops its products for immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. The company has collaboration with Biocon Ltd, for licensing opportunities of its pipeline product. Equillium is headquartered in California, the US.
The operating loss of the company was US$37.8 million in FY2021, compared to an operating loss of US$29.6 million in FY2020. The net loss of the company was US$39.1 million in FY2021, compared to a net loss of US$29.8 million in FY2020.
Quick View – Itolizumab
|Highest Development Stage|